ADMA 12.0000 Adma Biologics $ADMA Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 10:09 AM

ADMA 12.0000 Adma Biologics $ADMA Hit a 52 week high of 13.5300 Currently at 12.0000 -0.2500 -2.04% With a day low of 10.7400 and a total volume of 17,200.

ADMA Adma Biologics Recent Headline News

ADMA Biologics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:14AM CST

ADMA: 12.0000 (-0.2500)

ADMA Biologics to Present at the 9th International Respiratory Syncytial Virus (RSV) Symposium
GlobeNewswire - Mon Nov 10, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), announced today that it will be presenting data describing the composition and efficacy in an animal model of its polyclonal IVIG product, RI-002, at the 9th International Respiratory Syncytial Virus (RSV) Symposium, in Cape Town, South Africa. The abstract is titled: "Treatment of Normal and Immune Suppressed Cotton Rats with IVIG Containing High Titer Neutralizing Anti-RSV Antibody."
ADMA: 12.0000 (-0.2500)

ADMA Biologics Reports Third Quarter 2014 Financial and Operational Results
GlobeNewswire - Mon Nov 10, 6:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the third quarter ended September 30, 2014 and announced recent Company developments and anticipated milestones for the remainder of 2014.
ADMA: 12.0000 (-0.2500)

ADMA Biologics Approved for Trading on NASDAQ
GlobeNewswire - Wed Nov 05, 3:38PM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that the NASDAQ stock market has approved ADMA's common stock for listing on the NASDAQ Capital Market and is expected to begin trading on November 10, 2014 under the symbol "ADMA."
ADMA: 12.0000 (-0.2500)

ADMA Biologics to Present "Ascending Company" Presentation at BioNJ CEO Summit
Business Wire - Thu Oct 16, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the BioNJ CEO Summit Conference at 9:30 AM ET on October 21, 2014 at the Bridgewater Marriott, in Bridgewater, New Jersey.
ADMA: 12.0000 (-0.2500)

ADMA Biologics' Plasma Collection Subsidiary ADMA BioCenters Norcross, GA Facility Expands Global Regulatory Approval Presence
Business Wire - Wed Sep 10, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its wholly owned subsidiary, ADMA BioCenters in Norcross, Georgia, received approval from the Korean Ministry of Food and Drug Safety (MFDS) for the sale of source plasma into South Korea.
ADMA: 12.0000 (-0.2500)

ADMA Biologics Reports Second Quarter 2014 Financial and Operational Results
Business Wire - Mon Aug 11, 3:35PM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the second quarter ended June 30, 2014 and announced recent company developments and anticipated milestones for 2014.
ADMA: 12.0000 (-0.2500)

ADMA Biologics Forms Scientific Advisory Board with Expertise in Immune Deficiencies, Infectious Diseases and Transplantation
Business Wire - Mon Jun 16, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the formation of its Scientific Advisory Board (SAB) with the following appointments: R. Michael Blaese, M.D., Roy F. Chemaly, M.D., M.P.H., John DeVincenzo, M.D., Richard O'Reilly, M.D., Jordan S. Orange, M.D., Ph.D., and E. Richard Stiehm, M.D.
ADMA: 12.0000 (-0.2500)

ADMA Biologics to Present at 9th Annual JMP Securities Healthcare Conference on June 24
Business Wire - Fri Jun 13, 3:15PM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that Adam Grossman, ADMA's President, Chief Executive Officer and founder, is scheduled to present a company overview at the conference on Tuesday, June 24, 2014 at 12:00 p.m. EDT, at The Westin New York Grand Central Hotel, New York, NY.
ADMA: 12.0000 (-0.2500)

ADMA Biologics to Present Company Overview at the 13th Annual Needham Healthcare Conference
Business Wire - Mon Mar 31, 6:30AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that Adam Grossman, ADMA's President, Chief Executive Officer and founder, is scheduled to present a company overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 8:00 a.m. EDT. The conference will be held from April 8-9, 2014 at The Westin New York Grand Central Hotel, New York, NY.
ADMA: 12.0000 (-0.2500)

ADMA Biologics Reports Year End 2013 Results
Business Wire - Fri Mar 28, 6:15AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.
ADMA: 12.0000 (-0.2500)

ADMA Biologics Secures up to $15 Million Loan Commitment from Hercules Technology Growth Capital
Business Wire - Thu Feb 27, 7:00AM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it has secured a loan commitment for up to $15 million from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), a leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets.
HTGC: 16.08 (-0.02), ADMA: 12.0000 (-0.2500)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beazer Homes Sale Scrutinized for Shareholder Impact

Spotlight on Beazer Homes' Proposed Sale Here's a real head-scratcher for folks in the stock trenches: Beazer Homes USA, Inc. (NYSE: BZH) finds itself under the microscope with Halper Sadeh LLC stirring the pot. You can't make this up—just another day in the world of investor rights and looming litigation. Questions Arise Over Shareholder Gains Halper Sadeh LLC, that...

CME Group Smashes FX Open Interest Record Again

Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...

Automotive ECU Market Aims $160B by 2033

Automotive ECUs Under the Spotlight Picture this: By 2033, the automotive ECU market is expected to balloon to a whopping $160.59 billion. That's some serious cash, and it ain't just pocket change. This $47 billion jump from 2026 isn't just happening by accident—it's got everything to do with high-octane changes in the industry. With a 5.1% CAGR, you best believe it's a...

Universal Music Wraps €250M Share Buyback Plan

Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...

Withings and FFBB Team Up for Healthier Hoops

Withings Joins Forces with French Basketball Elite When it comes to linking technology and sports, nothing quite shows promise like Withings teaming up with the French Basketball Federation (FFBB). Picture this: a French startup that's crafted its legacy on cutting-edge health tech now throws its lot in with a nation proud of its basketball prowess. It's the kind of...

Regan Hutsell Shines as 99th Miss America Winner

There's a buzz in the air that's hard to ignore—Regan Hutsell from Texas secured the legendary Miss America crown. This event isn't just another chapter in the pageant's nearly century-old saga, but it's a spotlight moment that nods to Miss America's long-enduring cultural resonance. Now, you might be wondering: With all eyes on this Texan, what ripples could she send...

Thermoplastic Polyimide: A $0.86 Billion Market by 2032

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

Sony Expands Versatile Wireless Headphone Lineup: 2026

Renewed Focus on Sound: Sony's Latest Headphones Sony's dipping into the headphone market this time with a splash of style and sound signature updates. We've got the WH-1000XM4C, a next-gen version of the top-dog noise-cancelling cans, that are gonna catch the eye of every audiophile and traveler out there. WH-1000XM4C: The Flagship gets a Lift What they're offering is...

Hoymiles' V2X Charger Revamps Home Energy Control

Revolutionizing Home Energy with Hoymiles Here's a twist in the world of home energy that'll make any enthusiast pause—Hoymiles has launched their V2X DC Charger. This little number isn’t just a step up; it’s a giant leap toward integrating electric vehicles (EVs) into your home's energy system like never before. Nestled in Hangzhou, they've rolled this out as a...

Lab Glassware Market Set for Steady Growth by 2031

When you dive into the world of laboratory glassware, it might look like it's all pipettes and test tubes, but there's more bubbling under the surface. This market's got its eyes on a neat little climb from $7,630 million in 2026 to a forecasted $9,170 million by 2031. Ain't just speculation—this one's solid muscle growing at a comfortable 4.0% compound annual growth...